Income Tax penalty demand of Rs 9.38 Crore; company to appeal

Regulatory & Legal View source PDF Explain this filing

PANACEABIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.3%Reaction day

₹409.00

prior close

₹415.95

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.8%-2.5% vs market

Pharmaceuticals peers, median of 153sector-0.8%-2.5% vs sector

On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.5

10m

+3.5

15m

+2.6

30m

+2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.3-0.8-2.5-0.8-2.5

Next day

-6.3-0.8-5.4-1.0-5.3

-7.1+0.6-7.7-0.1-7.0

-7.7+0.8-8.4-0.2-7.5

-6.8+1.7-8.5+0.7-7.6

-9.8+2.0-11.7+0.4-10.2

-6.4+1.3-7.7+1.8-8.1

15d

-5.9-7.1+1.2-5.9+0.0

-11.4-6.8-4.6-7.7-3.7

-19.6-7.1-12.4-8.2-11.4

-27.3-15.7-11.5-16.5-10.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Panacea Biotec received three Income Tax demand orders dated December 24, 2025 from the Assistant Commissioner of Income Tax in Delhi, imposing penalty of about Rs 9.38 Crore under Section 270A of the IT Act for alleged under-reporting of income. Demand covers Assessment Years 2017-18 (Rs 5.55 Crore), 2020-21 (Rs 3.11 Crore) and 2021-22 (Rs 0.72 Crore). The company says the demand is not maintainable and is filing an appeal with the appellate authority.

Likely market impact

Company plans to appeal, calls demand not maintainable. No material financial or operational impact expected for now, though appeal outcome remains uncertain.